Rare diseases
Investigational molecules
Locations
When applied as an eye drop, the polymer forms a thin, moist film that coats the ocular surface. This film helps to retain water and to reduce friction between the eyelid and the surface of the eye or an ocular prosthesis.
Beyond the registered trials, the product information in the registry describes the substance as an authorised medicine for ophthalmic use, which is consistent with its role as a tear substitute for dry or irritated eyes, although the registry data provided here do not list further authorised indications.[2]
The combination product is formulated as eye drops, solution, and is given by ophthalmic use, meaning it is instilled directly into the eye.[2] In the completed trial, the dose used was 4 drops of the Hylan solution.[2] The comparison arms in the same trial used retinol palmitate (vitamin A) ophthalmic ointment, given as one dosage form, and FML Liquifilm 0.1% (fluorometholone) eye drops, given as 2 drops.[2]
Two Phase 3 trial records are registered for this substance combination. One trial, with the EU CT number 2023-504451-27-01, was completed and enrolled 40 participants.[2] The other, 2023-504451-27-00, was withdrawn before it started and had a planned enrolment of 100 participants.[1] Both trials had the same objective: to compare artificial tears, topical vitamin A ointment and low-dose topical steroids in people with an artificial eye who have chronic irritation or excess discharge.[2][1]
The main measure in both trial records was the change in discomfort score and discharge score from baseline after two weeks of use of one of the three treatments.[2][1] In plain words, the trials asked whether the eye drops or ointments reduced the feeling of irritation and the amount of discharge over a two-week period. The completed trial was interventional, meaning participants were assigned to a treatment.[2]
Participants in these trials were people who wore an ocular prosthesis and had chronic mucopurulent discharge or discomfort of the socket. The registry records do not provide further details on age limits or other inclusion criteria.[2][1] Because one of the two trials was withdrawn, the available evidence on this comparison comes from the completed trial with 40 participants.[2]
Because the product is authorised as a medicine, its safety information is assessed through the usual pharmacovigilance channels, but no specific adverse events are listed in the trial data supplied.[2]
Each condition opens its own overview and trial list
Recruiting trials first
Tell us about your condition – we search every trial in Europe and connect you with the right site.
